BPC 157 Peptide and Lyme Disease: Tissue Repair and Immune Support BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with BPC 157 promoted in vivo and in vitro angiogenesis. a Representative Download Scientific Diagram FDA Is Expected to Lift Restriction on Peptides, Heeding RFK Jr.'s Wishes The New York Times